MedTrace Logo

Malaysia Stop Tyrosine Kinase Inhibitor Trial

NCT02381379 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2020-09-14

No results posted yet for this study

Summary

To compare administration of peginterferon-α-2a for 1 year versus observation after stopping tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) patients with deep MR ≥ 2 years.

Conditions

  • Leukemia, Chronic Myeloid

Interventions

DRUG

Peginterferon-α-2a

Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.

Sponsors & Collaborators

  • Ministry of Health, Malaysia

    lead OTHER_GOV

Principal Investigators

  • Kian Meng Chang, FRCP(London) · Ampang Hospital, Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-10-31
Completion
2021-10-31

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02381379 on ClinicalTrials.gov